Yes, “KPop Demon Hunters” makes the list. But that was just one of the standouts in a great year. By Maya Phillips My list of favorite animation this year includes time-traveling rainbow people, ...

4D Molecular Therapeutics (FDMT) slipped ~15% on Wednesday after the company announced updated data from an early-stage trial for 4D-710, its experimental therapy for a genetic disorder known as ...

The architecture, engineering, and construction (AEC) sector has always depended on visualization technology. From hand-drawn sketches to blueprints, to CAD models and photorealistic renderings, each ...

4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all ...

A stunning new video, made from Mars Express orbiter data, allows you to soar over a gigantic maze on the Red Planet in incredible detail. When you purchase through links on our site, we may earn an ...

Nvidia is open sourcing Audio2Face, its AI tool that generates facial animations for 3D avatars based on audio input. Nvidia is open sourcing Audio2Face, its AI tool that generates facial animations ...

Nvidia has announced that its Audio2Face animation technology is going open source. On paper, that should make it much easier for a wide range of game developers to create AI characters with ...

For more than half a century, Spider-Man has done whatever a spider can — and more — across our TV screens in animated form. He has shaped generations of Marvel fans long before the MCU turned him ...

Entertainment and media companies are increasingly exploring generative AI, and the animation industry is grappling with divisive questions of how to integrate AI-powered tools into the creative ...

Video game adaptations don’t have the best track record, but Arcane bucks the trend. Based on the League of Legends universe, the series pleased fans while remaining accessible to newcomers. Archer's ...

4D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema (DME) and sending its stock up more than 40% in premarket trading. The ...